Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Quince Therapeutics secures USPTO nod for A-T treatment patent
SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...
Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia
Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...
Yahoo Finance11d
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary ...